|
業務類別
|
Biotechnology |
|
業務概覽
|
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. |
| 公司地址
| 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129 |
| 電話號碼
| +1 617 337-4680 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.solidbio.com |
| 員工數量
| 121 |
| Mr. David Tyronne Howton |
Chief Operating Officer and Secretary |
美元 513.42K |
23/04/2026 |
| Mr. Alexander G. Cumbo |
President, Chief Executive Officer and Director |
美元 650.99K |
23/04/2026 |
| Mr. Kevin Tan |
Treasurer, Chief Financial Officer and Principal Accounting Officer |
-- |
23/04/2026 |
| Dr. Paul Herzich, PhD |
Chief Technology Officer |
-- |
23/04/2026 |
| Dr. Jessie Hanrahan, PhD |
Chief Regulatory and Preclinical Operations Officer |
-- |
23/04/2026 |
| Dr. Gabriel Brooks, M.D. |
Chief Medical Officer |
美元 502.16K |
23/04/2026 |
|
|
| Mr. Ian F. Smith |
Executive Chairman of the Board |
23/04/2026 |
| Dr. Sukumar Nagendran, M.D. |
Independent Director |
23/04/2026 |
| Dr. Martin Freed, F.A.C.P.,M.D. |
Independent Director |
23/04/2026 |
| Mr. Alexander G. Cumbo |
President, Chief Executive Officer and Director |
23/04/2026 |
| Mr. Ilan Ganot |
Director |
23/04/2026 |
| Mr. Adam Stone |
Independent Director |
23/04/2026 |
| Ms. Lynne Sullivan |
Independent Director |
23/04/2026 |
| Dr. Georgia Keresty, M.P.H.,PhD |
Independent Director |
23/04/2026 |
| Dr. Clare Kahn, PhD |
Independent Director |
23/04/2026 |
|
|
|
|
